Last reviewed · How we verify

Rectal pain — Treatment Landscape & Competitive Intelligence

Rectal pain (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Rectal pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Galzin ZINC ACETATE Eton zinc acetate 1980-01-01
Sudafed PE phenylephrine Generic (multiple manufacturers) Alpha-1 adrenergic agonist (decongestant/vasopressor) Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor 1976-01-01
Phenergan Vc W/ Codeine PHENYLEPHRINE BITARTRATE ANI Pharmaceuticals Nonsteroidal Anti-inflammatory Drug [EPC] Alpha-1B adrenergic receptor 1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Rectal pain
  2. ANI Pharmaceuticals · 1 drug in Rectal pain
  3. Eton · 1 drug in Rectal pain
  4. Generic (multiple manufacturers) · 1 drug in Rectal pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Rectal pain:

Cite this brief

Drug Landscape (2026). Rectal pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/rectal-pain. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing